VERU — Veru Inc.

Summary of Veru Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $5.3 million, or $0.26 per diluted share, improved from a net loss of $8.9 million, or $0.61 per diluted share, in the prior year.
• Research and Development Costs: Decreased to $1.3 million from $5.7 million year-over-year, primarily due to the completion of the Phase 2b quality clinical study for Novosarm.
• General and Administrative Expenses: Reduced to $4.1 million from $5.2 million, attributed to lower share-based compensation.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $33 million, up from $15.8 million at the end of September 2025, bolstered by a public offering that generated $23.4 million in net proceeds.
• Net Working Capital: Increased to $29.7 million from $11.1 million as of September 30, 2025.

2. Strategic Updates and Business Highlights

• Drug Development: Focus on two key assets:
  • Novosarm: Aiming to enhance weight loss in older patients by combining it with GLP-1 receptor agonists, preserving lean mass while promoting fat loss.
  • Cabozantinib: Targeting anti-inflammatory effects to combat atherosclerotic cardiovascular disease.
• Regulatory Clarity: Positive feedback from the FDA regarding Novosarm's development pathways, with two potential regulatory routes based on weight loss and functional benefits.
• Upcoming Clinical Trials: The Phase 2b PLATO study is set to begin, evaluating Novosarm's effects on weight and physical function in older patients starting semaglutide treatment.

3. Forward Guidance and Outlook

• The company expects its cash reserves to fund operations through the interim analysis of the Phase 2b PLATO study, anticipated in 2027.
• Continued focus on developing Novosarm as a next-generation obesity treatment, with an emphasis on regulatory approval based on both weight loss and functional outcomes.

4. Bad News, Challenges, or Points of Concern

• Profitability: The company remains unprofitable with ongoing negative cash flow from operations.
• Clinical Risks: The reliance on the success of the upcoming PLATO study and the potential for weight loss plateau in patients using GLP-1 receptor agonists could impact outcomes.
• Market Competition: The competitive landscape for obesity treatments is intensifying, particularly with established GLP-1 receptor agonists and emerging therapies.

5. Notable Q&A Insights

• Study Design Choices: Management clarified the decision to use injectable semaglutide over oral formulations in the PLATO study to minimize variability and ensure consistency with prior studies.
• FDA Discussions: The FDA has shown interest in using stair climb tests as a functional measure, with specific recommendations for study design to ensure robust data collection.
• Interim Analysis: No pre-specified futility analysis or sample size adjustments are planned for the interim analysis, focusing instead on confirming lean mass preservation and fat loss.

This summary encapsulates Veru Inc.'s current financial health, strategic initiatives, and outlook while addressing potential risks and insights from the Q&A session.